No longer trading

Acquired by Eli Lilly and Company

The acquisition closed on June 24, 2026 (SEC 8-K 2.01). Its last closing price was on June 23, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from May 27, 2026. Source: SEC 8-K 2.01

CNTA

Centessa Pharmaceuticals plc CNTA

NasdaqMid CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

Final 13F Pro quality score

Final rank #2,748 of 2,854 · as of May 27, 2026

Why it scores 16Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$0

Quarter to Mar 31

Net income

$-79.24M

Quarter to Mar 31

Reading the latest SEC filing…

Key Metrics

Revenue

Q1 2026
EDGAR

Net Income

Q1 2026
EDGAR

EPS (Diluted)

Q1 2026
EDGAR

ROIC

Q1 2026
EDGAR

Debt/Equity

Q1 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CNTA

Earnings Per Share

13fpro.ai/company/CNTA

Loading ratio trend…

CNTA key financials by period

Reported revenue, net income and operating margin by fiscal year, from Centessa Pharmaceuticals plc's annual filings on SEC EDGAR.

Centessa Pharmaceuticals plc reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$15.0M$-197.5M—
FY 2023$6.9M$-151.1M—
Source: CNTA filings on SEC EDGAR →

CNTA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Centessa Pharmaceuticals plc (CNTA): stock profile, AI score and financials

Acquired by Eli Lilly and Company: Centessa Pharmaceuticals plc (CNTA) no longer trades and has left 13F Pro's AI-ranked universe. The acquisition closed on June 24, 2026 (SEC 8-K 2.01). Its last closing price was on June 23, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from May 27, 2026. Centessa Pharmaceuticals plc (CNTA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks CNTA using direct SEC EDGAR data and AI-powered research tools. CNTA trades on the Nasdaq exchange and files with the SEC under CIK 1847903. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CNTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Centessa Pharmaceuticals plc directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1847903 →